New Nipah vaccine proves safe, triggers antibodies in phase 1 results: Lancet study

A phase 1 randomised clinical trial of a novel Nipah virus vaccine, led by US researchers, may soon pave the way to prevent ...
The Manila Times

Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer

Study at the University of Colorado Anschutz Cancer Center builds on preclinical data showing that cirtuvivint plus PARP inhibition overcame resistance in preclinical models of high‑grade serous ovari ...
Seeking Alpha

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics' KT-621 demonstrated strong proof-of-concept as an oral STAT6 degrader, showing biologic-like efficacy in phase 1 healthy volunteer data. Results from phase 1b BroADen study, using ...
Nasdaq

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based ...
Health and Me on MSN

New Nipah virus vaccine passes phase 1 safety test, shows strong antibody response: Lancet study

Phase 1 trial results published in The Lancet show a new Nipah virus vaccine is safe and triggers an immune response, raising hope for preventing a deadly infection with no approved treatment. Keep ...

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...
Business Wire

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...
Morningstar

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) -Clinical data to date supports a potentially ...
ascopubs.org

A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors.

Monotherapy of envafolimab in patients with high tumor mutational burden advanced solid tumors: Results from a phase II clinical trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...